Gladly Thymus,
"
Director for Strategy, Dr Roger Aston
We’ve had verbal confirmation from a major regulatory authority that BrachySilTM is expected to be categorised as a “device” instead of a “drug”. Because the registration process is typically shorter than the regulatory process involving a pharmaceutical drug, we believe a shorter timeframe is feasible."
http://www.sec.gov/Archives/edgar/data/1314102/000114420405005323/ex99.htm
An IDE was submitted with the FDA. Roger was as bold as to inform the markets that the application would succeed... alas 10+ years later, the company still hasn't come to terms with rejection.
Gladly Thymus, " Director for Strategy, Dr Roger Aston We’ve had...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.010(0.86%) |
Mkt cap ! $21.74M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.17 | $1.14 | $80.47K | 69.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2150 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 7380 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |